Liquid Biopsy for Pathogens: Diagnosing Infections in Cancer Patients and an Emerging Biomarker Frontier

Time: 2:45 pm
day: Day Two


  • Infections play a critical role in cancer patients’ course of disease and outcome, with approximately 50% of deaths in cancer patients thought to be linked to infections as a primary or associated cause of death
  • Microbial cell-free DNA (mcfDNA) offers a liquid biopsy solution for infectious disease diagnostics with established value for immunocompromised patients
  • As a new molecular biomarker, mcfDNA may offer insights that expand beyond infectious diseases and toward a growing number of additional therapeutic areas, including gut, oncology, and other autoimmune diseases